R406

R406

• CAS Number: 841290-81-1
• UNSPSC Description: R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation[1]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[2].
• Target Antigen: Apoptosis; FLT3; Syk
• Type: Reference compound
• Related Pathways: Apoptosis;Protein Tyrosine Kinase/RTK
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/R406.html
• Purity: 96.70
• Solubility: DMSO : ≥ 61 mg/mL
• Smiles: COC1=CC(NC2=NC(NC3=NC(N4)=C(C=C3)OC(C)(C)C4=O)=C(C=N2)F)=CC(OC)=C1OC.OS(C5=CC=CC=C5)(=O)=O
• Molecular Weight: 628.63
• References & Citations: [1]Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008.|[2]Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8.ACS Infect Dis. 2021 Mar 12;7(3):661-671.|Ann Transl Med. 2019 Dec;7(23):758.|Arthritis Rheumatol. 2018 Sep;70(9):1419-1428. |Atherosclerosis. 2019 Oct;289:132-142.|bioRxiv. 2022 Dec 21, 519945.|bioRxiv. 2024 Apr 9.|Blood Adv. 2024 Nov 12;8(21):5653-5662.|BMC Cardiovasc Disord. 2024 Jul 12;24(1):354.|Cell Commun Signal. 2024 Apr 2;22(1):210.|Cell Rep. 2023 Mar 20;42(3):112275.|Cell. 2018 Oct 4;175(2):442-457.e23.|Exp Hematol Oncol. 2022 Nov 8;11(1):88.|Front Pharmacol. 2022 May 5;13:885053.|iScience. 2024 June 28.|iScience. 2024 Mar 25.|J Biol Chem. 2018 Apr 27;293(17):6410-6433.|J Pharmacol Sci. 2017 May;134(1):29-36.|Mol Immunol. 2024 Jul 31:173:88-98.|Nat Commun. 2022 Apr 19;13(1):2136.|Nihon University. School of Medicine. 2014 Mar.|Redox Biol. 3 September 2022, 102461.|Scand J Immunol. 2024 Apr 26:e13371.|Theranostics. 2021 May 24;11(15):7308-7321.|Adv Mater. 2024 Mar 15:e2311283.|Harvard Medical School LINCS LIBRARY|iScience. 2024 Jan 8.|Mater Today Bio. 2024 Mar 22, 101037.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2023 Jun 29.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported